3744 Ergovaline Ergovaline is a solid compound with the chemical formula C29H35N5O5. Ergovaline belongs to the lysergic acids and derivatives, a subclass of ergoline and derivatives within the organic compounds. With an average molecular weight of 533.62 g/mol, Ergovaline is a heavy molecule. This exogenous substance has been found in or released from 13 recorded sources, including electrical and electronic equipment such as cell phones, capacitors, wires and cables, batteries, and printed circuit boards; textiles, leather and furnishings, including synthetic textiles, carpets and rugs; food packaging; medical devices; and lubricants used in energy, oil, gas, industrial manufacturing, and chemical processing. Recorded exposure routes include inhalation, oral, and touch. The compound interacts with seven recorded protein targets. Ergovaline acts as an agonist at the D(2) dopamine receptor (DRD2), inhibiting cyclic AMP production and creating second messenger responses similar to those of dopamine. It also acts as an agonist at vascular 5-hydroxytryptamine receptors 2A (HTR2A), 1B (HTR1B), and 1D (HTR1D), which causes the constriction of blood vessels. Additionally, Ergovaline acts as a partial agonist at alpha-1 adrenoreceptors, specifically the Alpha-1A adrenergic receptor (ADRA1A), Alpha-1B adrenergic receptor (ADRA1B), and Alpha-1D adrenergic receptor (ADRA1D), thereby inhibiting the contractile response to norepinephrine. 2873-38-3 104843 C29H35N5O5 533.6 White powder. Oral, dermal, inhalation, and parenteral (contaminated drugs). (A3101) Ergoline alkaloids tend to act as a group, producing complex and variable effects of partial agonism or antagonism at adrenergic, dopaminergic, and serotonergic receptors. Variables relating to these effects are influenced by the agent, dosage, species, tissue, physiological, and endocrinological state, and experimental conditions. In particular, ergoline alkaloids have been shown to have the significant affinity towards the 5-HT1 and 5-HT2 serotonin receptors, D1 and D2 dopamine receptors, and alpha-adrenergic receptors. This can result in a number of different effects, including vasoconstriction, convulsions, and hallucinations. (A2914, A2915, A2916) No indication of carcinogenicity to humans (not listed by IARC). Ergovaline is an ergopeptine and alkaloid of the ergoline family. Like other ergoline alkaloids, it occurs in various species of vines of the Convolvulaceae (morning glory) family and in some species of lower fungi. (L1918) Ingestion of ergoline alkaloids is known to cause the disease ergotism. Ergotism occurs in two forms, gangrenous and convulsive, likely depending on the different kinds and amounts of ergoline alkaloids present. (A2913) Convulsive ergotism can cause painful seizures and spasms, diarrhea, paresthesias, itching, headaches, nausea and vomiting. Usually the gastrointestinal effects precede the central nervous system effects. As well as seizures there can be hallucinations and mental effects including mania or psychosis. Gangrenous ergotism causes dry gangrene as a result of vasoconstriction induced in the more poorly vascularized distal structures, such as the fingers and toes. Symptoms include desquamation, weak periphery pulse, loss of peripheral sensation, edema and ultimately the death and loss of affected tissues. (L1920) Treatment for ergotism consists of vasodilators, anticoagulants and low molecular weight dextrans. If necessary, a sympathetic nerve blockade may be carried out, such as brachial plexus blockade. Temporary sedation (e.g. haloperidol) will be necessary in hallucination and diazepam is used for convulsions. There is no specific antidote. (L1921) 2010-04-23T21:10:16Z 2026-08-22T09:07:47Z http://en.wikipedia.org/wiki/Ergovaline true CC(C)C1N2C(=O)C(C)(NC(=O)C3CN(C)C4CC5=CNC6=CC=CC(=C56)C4=C3)OC2(O)C2CCCN2C1=O C29H35N5O5 InChI=1S/C29H35N5O5/c1-15(2)24-26(36)33-10-6-9-22(33)29(38)34(24)27(37)28(3,39-29)31-25(35)17-11-19-18-7-5-8-20-23(18)16(13-30-20)12-21(19)32(4)14-17/h5,7-8,11,13,15,17,21-22,24,30,38H,6,9-10,12,14H2,1-4H3,(H,31,35) BGHDUTQZGWOQIA-UHFFFAOYSA-N 533.6187 533.263819255 Exogenous Solid 1.4 94635 CHEM002660 DTXSID10893243 NS00094895 (6aR,9R)-N-[(1S,2S,4R,7S)-2-hydroxy-4-methyl-5,8-dioxo-7-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide 118.21000000000002 144.5444 56.35974126088264 3 6 3 9.695485603868692 7.7804845304204955 1 7 2.44 -3.10 4.26e-01 g/l Organic compounds Alkaloids and derivatives Ergoline and derivatives Lysergic acids and derivatives 219 CED0011785 BGHDUTQZGWOQIA-UHFFFAOYSA-N 440000000000000000000000200a01000000000000000000006000000100000d00000010000000200000008080002000000000000080400200000000020800000008000001800000000000000000002000208000000840000008000012000000001000000300080000000000000000000000020201000000100000804000001008010000480020008000002000000040a0000400000000000000080000000020400400008004000001000000480000000000000000000000008000000000000000000000010000000000000000000000000000000000000020000300800001000000000000000000100041000000000400004008000000008010000400000000 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 776t3gAAAAAQAAAAAwAAAAAAAAAnAAAALQAAAIABBgBgAAAAAQMGAGAAAAAD AQYAYAAAAAEDBgBgAAAAAwEHACgAAAADAwYAKAAAAAMECAAoAAAAAwIGACAA AAAEBgBgAAAAAQMHAGgAAAADAgEGACgAAAADBAgAKAAAAAMCBgBgAAAAAwEG AGAAAAACAgcAIAAAAAMGAGAAAAABAwYAYAAAAAMBBgBgAAAAAgIGQCgAAAAD BAZAaAAAAAMDAQdAOAAAAAMBAwZAKAAAAAMEBkBoAAAAAwMBBkBoAAAAAwMB BkBoAAAAAwMBBkAoAAAAAwQGQCgAAAADBAYAKAAAAAMEBgBoAAAAAwMBCAAg AAAAAgYAIAAAAAQIAGAAAAABAQYAYAAAAAMBBgBgAAAAAgIGAGAAAAACAgYA YAAAAAICBwAoAAAAAwMGACgAAAADBAgAKAAAAAMCCwABAAECAAEDAAMEAAQF IAUGKAIFBwAHCAAHCQAJCiAKCygCCgwADA0ADQ4ADg8ADhAAEBEAERIAEhNo DBMUaAwUFWgMFRZoDBYXaAwXGGgMGBloDBkaaAwZGyAbHCgCBx0AHR4AHh8A HiAAICEAISIAIiMAIyQAJCUgJSYoAiUDAB4EACQgABwMABsQABoSaAwaFWgM QgcAAAAGAyUkIB4EBQUEHh0HBg0OEBscDAYREhoZGxAFExIaFRQGFhcYGRoV BSEgJCMiFwQAAAAAAAAAFg== 2026-09-19T04:00:52Z